Worldwide Selective Estrogen Receptor Degrader (SERDs) Industry to 2025 - USA to Dominate the Market
08 janv. 2021 11h13 HE
|
Research and Markets
Dublin, Jan. 08, 2021 (GLOBE NEWSWIRE) -- The "Selective Estrogen Receptor Degrader (SERDs) Market, Dosage, Price & Clinical Trials Insight 2025" report has been added to...
Axiom Presents “Clinical Studies in 2021: The changing dynamics and challenges of getting studies done rapidly” Insights Session at Biotech Showcase Digital during JP Morgan Healthcare Conference
06 janv. 2021 12h13 HE
|
Axiom Real-Time Metrics Inc
SAN FRANCISCO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services focused on small-to-medium life science...
Worldwide Indsutry for KRAS Inhibitors to 2025 - Players Include Amgen, Mirati Therapeutics & Revolution Medicines Among Others
06 janv. 2021 10h53 HE
|
Research and Markets
Dublin, Jan. 06, 2021 (GLOBE NEWSWIRE) -- The "Global KRAS Inhibitors Market Opportunity & Clinical Trials Outlook 2025" report has been added to ResearchAndMarkets.com's offering. The...
Global Real World Evidence Solutions Market to Reach US$1.9 Billion by the Year 2027
31 déc. 2020 06h38 HE
|
Research and Markets
Dublin, Dec. 31, 2020 (GLOBE NEWSWIRE) -- The "Real World Evidence Solutions - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Amid the...
Global Actinic (Solar) Keratosis Clinical Trials Review, H2, 2020 - 10 Companies Involved
23 déc. 2020 03h53 HE
|
Research and Markets
Dublin, Dec. 23, 2020 (GLOBE NEWSWIRE) -- The "Actinic (Solar) Keratosis Global Clinical Trials Review, H2, 2020" clinical trials has been added to ResearchAndMarkets.com's offering. "Actinic...
FDA Grants IND Approval for Phase 2 Clinical Trial of Innovation Pharmaceuticals’ Brilacidin for Treating COVID-19
21 déc. 2020 07h00 HE
|
Innovation Pharmaceuticals Inc.
Brilacidin’s potent in vitro inhibition of the Washington and Italian strains of SARS-CoV-2 support its potential to inhibit emerging coronavirus mutations (variants), such as those in the United...
PRA Health Sciences collaborates with PWNHealth and Fulgent Genetics to provide at-home COVID-19 test capabilities
17 déc. 2020 16h02 HE
|
PRA Health Sciences, Inc.
RALEIGH, N.C., Dec. 17, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today the enhancement of its COVID-19 Monitoring Program with the addition of at-home COVID-19 testing...
Ivy Brain Tumor Center Initiates Phase 0 Clinical Trial with BeiGene for Newly Diagnosed and Recurrent Glioblastoma
16 déc. 2020 07h00 HE
|
Ivy Brain Tumor Center
Phoenix, AZ, Dec. 16, 2020 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute today announced the opening of a Phase 0 clinical trial for patients with newly diagnosed...
Phathom Pharmaceuticals Announces Plans to Initiate Vonoprazan Development Program in Non-Erosive Reflux Disease (NERD)
14 déc. 2020 08h30 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Neoleukin Therapeutics Announces Submission of Investigational New Drug Application for NL-201 De Novo Protein Immunotherapy Candidate for Cancer
10 déc. 2020 08h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...